At the Interface of Tumor-Associated Macrophages and Fibroblasts: Immune-Suppressive Networks and Emerging Exploitable Targets [0.03%]
肿瘤相关巨噬细胞和成纤维细胞互作界面：免疫抑制作用及新兴靶点
Eleonora Timperi,Hugo Croizer,Darya Khantakova et al.
Eleonora Timperi et al.
Tumor-associated macrophages (TAM) constitute a prominent immune cell population within various solid cancers, playing a pivotal role in disease progression. Their increased numbers and frequencies often strongly correlate with resistance t...
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer [0.03%]
基于27个免疫相关基因的DetermaIO预测三阴性乳腺癌新辅助阿特朱单抗联合化疗疗效
Matteo Dugo,Chiun-Sheng Huang,Daniel Egle et al.
Matteo Dugo et al.
Purpose: We assessed the 27-gene RT-qPCR-based DetermaIO assay and the same score calculated from RNA sequencing (RNA-seq) data as predictors of sensitivity to immune checkpoint therapy in the neoTRIPaPDL1 randomized tria...
A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma [0.03%]
利珀利西单药治疗复发/难治外周T细胞淋巴瘤患者Ⅰb期临床研究
Jie Jin,Hong Cen,Keshu Zhou et al.
Jie Jin et al.
Purpose: Relapsed and/or refractory peripheral T-cell lymphoma (r/r PTCL) is an aggressive and heterogeneous hematologic malignancy with high unmet need. Previously, PI3K inhibitors were shown to be efficacious in B- and ...
AACR Cancer Progress Report 2024: Inspiring Science-Fueling Progress-Revolutionizing Care [0.03%]
2024年美国癌症研究协会抗癌进展报告：激发科学、推动进步、变革护理
Patrick A Williams,Sayyed Kaleem Zaidi,Rajarshi Sengupta
Patrick A Williams
Update on Whole-Body MRI Surveillance for Pediatric Cancer Predisposition Syndromes [0.03%]
儿科癌症易感综合征全身MRI监测最新进展
Mary-Louise C Greer,Lisa J States,David Malkin et al.
Mary-Louise C Greer et al.
Whole-body MRI (WBMRI) is an integral part of screening infants, children, and adolescents for presymptomatic neoplasms in certain cancer predisposition syndromes, which include Li-Fraumeni and constitutional mismatch repair deficiency synd...
Cancer in Multilineage Mosaic RASopathies due to Pathogenic Variants in HRAS or KRAS: A Systematic Review and Meta-analysis [0.03%]
HRAS或KRAS致病性变异引起的多谱系镶嵌RASopathy相关癌症的系统评价和meta分析
Jonas Windrich,Gina M Ney,Philip S Rosenberg et al.
Jonas Windrich et al.
Purpose: To determine the cancer risk and spectrum in patients with multilineage mosaic RASopathies with pathogenic variants (PV) in HRAS or KRAS. Experim...
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer [0.03%]
ABBV-011抗体偶联药物治疗小细胞肺癌的I期临床试验：一种针对SEZ6靶点的抗体偶联药物首次人体研究
Daniel Morgensztern,Neal Ready,Melissa L Johnson et al.
Daniel Morgensztern et al.
Purpose: Seizure-related homolog protein 6 (SEZ6) is a novel target expressed in small cell lung cancer (SCLC). ABBV-011, a SEZ6-targeted antibody conjugated to calicheamicin, was evaluated in a phase I study (NCT03639194...
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201) [0.03%]
克隆性造血和转移性去势抵抗性前列腺癌患者使用雄激素受体途径抑制剂的临床结果（联盟A031201）
Jeffrey L Jensen,Olivia Bobek,Irenaeus C C Chan et al.
Jeffrey L Jensen et al.
Purpose: Mutations in hematopoietic progenitor cells accumulate with age leading to clonal expansion, termed clonal hematopoiesis (CH). CH in the general population is associated with hematopoietic neoplasms and reduced o...
Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis [0.03%]
多组学谱分析区分了汗腺癌与良性汗腺肿瘤并为汗腺癌发生的遗传演变提供了见解
Gabriel J Starrett,Brittany C Baikie,Benjamin K Stoff et al.
Gabriel J Starrett et al.
Purpose: Sebaceous carcinoma is the third most common nonkeratinocyte skin cancer in the United States with 1,000 cases per year. The clinicopathologic features of sebaceous carcinoma and benign sebaceous neoplasms (adeno...
Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial [0.03%]
联合使用抗血管生成药物和PD1抑制剂治疗软组织肉瘤的预测及动态标志物：与IMMUNOSARC试验相关研究
David S Moura,Jesus M Lopez-Marti,Iva Benesova et al.
David S Moura et al.
Purpose: The IMMUNOSARC trial combined an antiangiogenic agent (sunitinib) with a PD1 inhibitor (nivolumab) in advanced sarcomas. Here, we present the first correlative studies of the soft-tissue sarcoma cohort enrolled i...